RxDoctor Payments DataLook up a doctor →

Wade Brosius, DO

Family Medicine · Royersford, PANPI 1043284763

Payments from drug & device makers

$180,088in general payments, 2019–2025

Across 584 payments — averaging $308.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$93K
  • Amgen$36K
  • AstraZeneca$26K
  • Bayer$11K
  • Exact Sciences$3K
  • Topcon Healthcare, Inc.$2K
  • plus $9K from 50 others

What the payments were for

  • Consulting fees$1,7508%
  • Speaking & faculty fees$11,17949%
  • Food & beverage$10,01043%
  • Education$430%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$180,088 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$168,126
Medicare patients
340
Services billed
2,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$61,333
EliquisApixaban39$50,938
JardianceEmpagliflozin29$40,631
AfrezzaInsulin Regular, Human26$35,248
MounjaroTirzepatide26$33,647
JanuviaSitagliptin Phosphate16$18,970
Tresiba Flextouch U-200Insulin Degludec17$17,728
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$15,966
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$12,761
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,265
FarxigaDapagliflozin Propanediol15$11,809
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$8,579
EntrestoSacubitril/Valsartan12$7,354
MyrbetriqMirabegron13$6,653
XareltoRivaroxaban14$6,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$991$67,29254 claims
PfizerEliquis$456$50,93839 claims
Boehringer IngelheimJardiance$520$40,63129 claims
Mannkind CorporationAfrezza$264$35,24826 claims
Lilly USA, LLCMounjaro$850$33,64726 claims
MerckJanuvia$326$18,97016 claims
GSKTrelegy Ellipta$485$12,26513 claims
AstraZenecaFarxiga$25,649$11,80915 claims
NovartisEntresto$332$7,35412 claims
Astellas Pharma US IncMyrbetriq$94$6,65313 claims
Johnson & JohnsonXarelto$142$6,35714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Royersford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →